Passive transdermal drug delivery is a convenient and effective way to administer a variety of therapeutics. This route of administration is both noninvasive and produces steady drug delivery over an extended period of time.
While conventional transdermal systems (such as drug patches) have demonstrated the benefits of delivering drugs via the skin, they only work for an extremely limited number of drugs. This is because millions of dead skin cells form a protective barrier on the surface of the skin (the stratum corneum) that prevents most therapeutic molecules from passing into the skin. Passive transdermal patches are typically limited to lipid-soluble drugs with a molecular weight of less than 500 daltons.
As a result of these limitations, researchers have explored a variety of methods to penetrate this skin barrier - ranging from chemicals to lasers, microneedles, and ultrasound. However, many of these technologies have drawbacks or other limitations. PassPort Technologies, Inc. is looking to overcome these challenges via a novel transdermal microporation platform called the PassPort® system.